Theranos, the embattled blood testing start-up, has devolved from the next great idea to a classic case of great ideas don't make great brands. The execution of that great idea is what makes a brand bankable.
Or at least that's how it should be. Unfortunately, a collective gold rush mentality can often result in brands being anointed before they're truly initiated. Execution, the very thing that will matter most to making them rich, cannot be an afterthought to blessing unproven potential with stacks of cash.
Certainly, investors shouldn't be deemed the losers if the game was rigged from the start. However, I think it's a fair to question if investors, even those risking as much as $96 million, were as execution as much as on the idea.
As always, thank you for reading and for sharing.